AEON Biopharma, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a high-stakes gamble on a specific regulatory interpretation. If AEON successfully navigates the 351(k) pathway and secures approval for ABP-450, it enters a $3.3 billion market with an industry-leading cost structure and a strategic pricing advantage. The validation from the FDA in early 2026 provides a glimmer of hope that the analytical-first approach is viable. However, the margin of error is non-existent. The company is operating on a cash-starved basis where a single regulatory delay or a failure to raise additional capital would be catastrophic. Investors are essentially weighing the probability of a successful 2026 BLA submission against the very real possibility of a liquidity crisis or a devastating regulatory setback. The outcome hinges entirely on the FDA's final determination of biosimilarity and the company's ability to maintain its fragile financial equilibrium.